Free Trial

Jyong Biotech (MENS) Competitors

$11.78 +0.63 (+5.65%)
As of 04:00 PM Eastern

MENS vs. HCM, IMVT, KYMR, CRNX, MOR, ALVO, RXRX, MIRM, CPRX, and NAMS

Should you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include HUTCHMED (HCM), Immunovant (IMVT), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

Jyong Biotech vs. Its Competitors

Jyong Biotech (NASDAQ:MENS) and HUTCHMED (NASDAQ:HCM) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

HUTCHMED has a consensus target price of $23.50, suggesting a potential upside of 32.17%. Given HUTCHMED's stronger consensus rating and higher possible upside, analysts clearly believe HUTCHMED is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
HUTCHMED
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

HUTCHMED has higher revenue and earnings than Jyong Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/AN/AN/AN/A
HUTCHMED$630.20M4.92$37.73MN/AN/A

In the previous week, Jyong Biotech had 3 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Jyong Biotech and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.80 beat Jyong Biotech's score of 0.45 indicating that HUTCHMED is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jyong Biotech
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
HUTCHMED
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

8.8% of HUTCHMED shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
HUTCHMED N/A N/A N/A

Summary

HUTCHMED beats Jyong Biotech on 7 of the 8 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MENS vs. The Competition

MetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$895.63M$773.27M$2.18B$9.49B
Dividend YieldN/A4.84%2.58%4.00%
P/E RatioN/A1.3822.1319.96
Price / SalesN/A24.9393.8982.69
Price / CashN/A19.5628.9258.45
Price / BookN/A6.8160.265.82
Net IncomeN/A-$4.28M-$121.56M$258.42M
7 Day Performance6.99%1.99%0.79%1.94%
1 Month PerformanceN/A4.61%2.34%12.02%
1 Year PerformanceN/A9.43%25.23%20.81%

Jyong Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MENS
Jyong Biotech
N/A$11.78
+5.7%
N/AN/A$895.63MN/A0.0031News Coverage
Quiet Period Expiration
HCM
HUTCHMED
2.8052 of 5 stars
$17.74
+0.9%
$19.00
+7.1%
-7.0%$3.09B$630.20M0.001,811Analyst Forecast
IMVT
Immunovant
1.0913 of 5 stars
$17.70
-1.2%
$36.30
+105.1%
-34.3%$3.03BN/A-6.46120Positive News
KYMR
Kymera Therapeutics
3.1557 of 5 stars
$45.14
-2.3%
$59.11
+31.0%
+6.8%$2.94B$47.07M-14.56170
CRNX
Crinetics Pharmaceuticals
3.6026 of 5 stars
$30.95
-0.5%
$69.50
+124.6%
-43.5%$2.90B$1.04M-8.10210Positive News
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
ALVO
Alvotech
2.8685 of 5 stars
$8.64
+0.1%
$16.00
+85.2%
-22.4%$2.60B$491.98M23.351,032
RXRX
Recursion Pharmaceuticals
0.8993 of 5 stars
$6.40
+9.6%
$7.00
+9.4%
-25.1%$2.60B$58.84M-3.62400Analyst Revision
High Trading Volume
MIRM
Mirum Pharmaceuticals
3.9526 of 5 stars
$51.95
+0.0%
$65.50
+26.1%
+32.0%$2.57B$336.89M-32.27140Positive News
CPRX
Catalyst Pharmaceuticals
4.9136 of 5 stars
$21.01
-0.1%
$32.83
+56.3%
+22.8%$2.56B$491.73M13.3880News Coverage
Positive News
NAMS
NewAmsterdam Pharma
3.6333 of 5 stars
$22.56
+1.6%
$41.30
+83.1%
+26.6%$2.53B$45.56M-12.004

Related Companies and Tools


This page (NASDAQ:MENS) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners